Business Context and Reporting Period
This Form 6-K filing by GlaxoSmithKline plc (GSK) covers the period ending July 25, 2017. The report details the announcement of clinical trial results for ViiV Healthcare, a global specialist HIV company established by GSK, Pfizer, and Shionogi. The filing focuses on the NEAT 022 study presented at the International AIDS Society meeting in Paris.
Key Financial Metrics
The filing text does not provide a clear value for revenue, profit, cash flow, margins, debt, or liquidity. This document is a current report regarding clinical trial data and does not contain financial statements or quarterly earnings results.
Material Changes and Clinical Results
The primary material update concerns the NEAT 022 study involving 415 patients with HIV and high cardiovascular risk (CVD) across six European countries. Key findings include:
- Study Design: Patients were randomized to switch from a boosted protease inhibitor (PI/r) regimen to a dolutegravir-based regimen or remain on PI/r for 48 weeks.
- Viral Suppression: Switching to dolutegravir was non-inferior to continuing PI/r in maintaining viral suppression (HIV RNA < 50 copies/mL). No emergent resistance mutations were observed.
- Lipid Profile: Total cholesterol and other lipid fractions (except high-density lipoprotein) improved significantly (p<0.001) in the dolutegravir group.
- Safety: There was no significant difference in severe, grade 3 or 4, or treatment-modifying adverse events between the groups.
Outlook, Risks, and Management Commentary
Management Commentary: Michael Aboud, Vice President and Global Medical Lead for dolutegravir, emphasized that the study confirms switching to dolutegravir maintains viral suppression while improving lipid profiles in high-risk populations. Jose M. Gatell, chief investigator, noted this is the first switching study targeting high CVD risk, validating a strategy to minimize cardiovascular risk through antiretroviral agent selection.
Risks and Contingencies: The filing includes standard safety information for TIVICAY (dolutegravir), including:
- Hypersensitivity: Reactions characterized by rash and organ dysfunction have been reported in <1% of subjects; immediate discontinuation is required if suspected.
- Hepatitis: Patients with Hepatitis B or C co-infection may face increased risks of transaminase elevations.
- Drug Interactions: Coadministration with certain inducers of UGT1A and/or CYP3A may reduce plasma concentrations.
- Forward-Looking Statements: GSK cautions that projections are subject to risks and uncertainties that may cause actual results to differ materially.
Key Facts for Investor Verification
- Verify the commercial impact of the NEAT 022 results on TIVICAY (dolutegravir) market share, particularly in the high cardiovascular risk patient segment.
- Confirm the timeline for potential label updates or guideline changes based on the demonstrated lipid profile improvements.
- Review the full prescribing information for TIVICAY regarding specific contraindications (e.g., dofetilide) and drug interaction management.
- Monitor ViiV Healthcare's broader pipeline and collaboration status with GSK, Pfizer, and Shionogi for future HIV treatment advancements.